20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies

Rhea-AI Summary

20/20 BioLabs (Nasdaq: AIDX) outlines advantages of its patented protein tumor marker (PTM) approach for multi-cancer early detection, citing May–Nov 2025 validation studies showing up to 50% sensitivity for some early-stage tumors and a blinded MD Anderson study reporting ~90% early-stage lung cancer detection.

The company advocates a tiered screening model using protein-based OneTest first, then ctDNA or imaging, and notes a Feb 2026 Medicare coverage pathway beginning in 2028.

Positive

• OneTest reported up to 50% sensitivity for some early-stage tumors (May 2025)
• Blinded MD Anderson study found ~90% early-stage lung cancer detection (Nov 2025)
• Large validation across >15,000 participants showed measurable Stage I sensitivity (Oct 2025)
• Potential Medicare pathway for MCED coverage starting 2028 (Feb 2026 legislation)

Negative

• Circulating tumor DNA (ctDNA) has a fundamental biological constraint in early-stage disease
• Company must continue building evidence and work with payers despite Medicare pathway

News Market Reaction – AIDX

-8.49%

4 alerts

-8.49% News Effect

-6.2% Trough Tracked

-$3M Valuation Impact

$28M Market Cap

0.5x Rel. Volume

On the day this news was published, AIDX declined 8.49%, reflecting a notable negative market reaction. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $28M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Early-stage detection rate: 50% Protein tumor markers: 7 markers Study participants: More than 15,000 participants +5 more

8 metrics

Early-stage detection rate 50% Some tumor types (e.g., pancreatic, ovarian) in pre-diagnostic population, May 2025 data

Protein tumor markers 7 markers AI-enhanced blood test integrating seven established protein tumor markers

Study participants More than 15,000 participants Multicenter validation study across USA, China, and Brazil

Study centers 7 centers Multicenter validation across three countries

Countries involved 3 countries USA, China, Brazil in Nature Precision Oncology validation study

Lung cancer detection Nearly 90% Early-stage lung cancers detected in blinded validation study at MD Anderson

Lead time before diagnosis 12–21 months Other cancers flagged prior to diagnosis in MD Anderson validation

Follow-up testing window 3–6 months Suggested interval between protein-based test and ctDNA-based testing

Market Reality Check

Price: $2.48 Vol: Volume 255,323 is below 2...

low vol

$2.48 Last Close

Volume Volume 255,323 is below 20-day average of 441,683, suggesting limited pre-news positioning. low

Technical Shares at $2.71 are trading below the $6.30 200-day MA and sit far under the $50.00 52-week high.

Historical Context

1 past event · Latest: Feb 25 (Positive)

Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	AI product launch	Positive	-28.8%	Launched OneTest for Longevity AI blood-test and risk platform.

Pattern Detected

Available history shows one seemingly positive commercial launch that coincided with a sharply negative price reaction.

Recent Company History

Over the past months, 20/20 BioLabs has highlighted commercial and technology milestones. On Feb 25, 2026, the company launched its AI-enabled OneTest for Longevity chronic disease risk platform, yet the stock fell 28.82% in the following 24 hours. Today’s announcement focuses on clinical and scientific support for its protein-based MCED platform. Together, the news flow emphasizes AI-driven diagnostics and protein biomarker screening while price action has remained weak versus the $50.00 52-week high.

Market Pulse Summary

The stock moved -8.5% in the session following this news. A negative reaction despite the scientific...

Analysis

The stock moved -8.5% in the session following this news. A negative reaction despite the scientific emphasis could fit a pattern where prior seemingly positive developments, like the Feb 25, 2026 AI-based launch that preceded a 28.82% decline, were met with selling. The article highlights encouraging metrics such as up to 50% early-stage detection and nearly 90% early lung cancer detection, but the market may focus on commercialization risk, competitive ctDNA technologies, and the gap until potential Medicare MCED coverage in 2028.

Key Terms

circulating tumor DNA, ctDNA, protein tumor marker, multi-cancer early detection, +4 more

8 terms

circulating tumor DNA medical

"limitations of circulating tumor DNA as first-line screening tests for early-stage disease"

Fragments of DNA shed by cancer cells into the bloodstream that act like tiny fingerprints of a tumor; they can be detected with a blood test rather than a biopsy. Investors care because circulating tumor DNA (ctDNA) enables faster, lower-cost ways to detect disease, track treatment response, identify emerging resistance and enroll patients in trials—factors that can materially affect the commercial prospects of diagnostics and therapeutics.

ctDNA medical

"compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs"

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

protein tumor marker medical

"its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer"

A protein tumor marker is a specific protein that is produced by cancer cells or released by the body in response to a tumor and can be measured in blood, urine or tissue to help detect, track or predict cancer activity. Investors care because marker tests drive demand for diagnostics, influence clinical trial results and regulatory decisions, and can determine the commercial success of drugs and tests—think of them as a car’s warning light that signals whether treatment or further action is needed.

multi-cancer early detection medical

"multi-cancer early detection (MCED) methodology in the wake of several recent studies"

A multi-cancer early detection test is a medical screening tool—often a simple blood test—that looks for biological signals, such as abnormal DNA or protein patterns, that could indicate many different cancers before symptoms appear. For investors it matters because successful tests can reshape demand for diagnostics, influence healthcare spending and insurance coverage, and create new revenue streams or risks for companies across diagnostics, treatment and screening services; think of it as a smoke alarm that can warn of problems throughout an entire house rather than just one room.

Stage I medical

"measurable sensitivity even in Stage I disease and progressively higher detection rates"

Stage I describes an early phase of cancer in which a tumor is small and confined to its original location without evidence of spread to lymph nodes or distant organs. For investors, Stage I findings matter because early-stage disease typically requires less aggressive treatment, has better patient outcomes, and can influence the size and timing of market opportunities for diagnostics, therapies or screening tools—think of detecting a small fire before it spreads.

oncogenesis medical

"supporting the sensitivity of protein tumor markers during early oncogenesis"

Oncogenesis is the biological process by which normal cells change and begin to grow uncontrollably, forming cancer. Think of it as a construction crew that loses oversight and builds unsafe, expanding structures; understanding how and why this happens guides drug developers and regulators in creating treatments. Investors care because breakthroughs or setbacks in preventing or reversing oncogenesis can directly affect the value and risk profile of companies working on cancer diagnostics, therapies, and related technologies.

machine learning technical

"protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer"

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

Medicare coverage regulatory

"Congress passed legislation in February 2026 to create a pathway for Medicare coverage of MCEDs"

Medicare coverage is the set of health insurance benefits provided by the U.S. federal Medicare program that pays for hospital care, doctor services, prescription drugs and certain medical supplies for eligible beneficiaries. Investors pay attention because changes in what Medicare will cover, how much it reimburses, or who qualifies can materially affect revenue and pricing for hospitals, drugmakers, medical device manufacturers and insurers—like rewriting the rulebook for a very large, steady customer.

AI-generated analysis. Not financial advice.

Protein Biomarkers May Play an Important Role in Overcoming Limitations of Circulating Tumor DNA for Screening Early-Stage Cancers

GAITHERSBURG, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detection (MCED) methodology in the wake of several recent studies suggesting the expected value of this approach for earlier stage detection compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs.

As population-scale cancer screening studies continue to generate trial data and real-world evidence, the medical community, consumers, investment community, and scientific experts are increasingly focused on which MCEDs and biomarker modalities are best suited to detect cancers early enough to meaningfully change patient outcomes. Results reported in February 2026 from a large-scale ctDNA-based MCED study conducted in the U.K. has prompted broader discussion about the biological limitations of circulating tumor DNA as first-line screening tests for early-stage disease.

Generally, for MCED tests to be clinically meaningful, they must detect cancer early enough to change outcomes. Among other things, this requires biomarkers that are present and detectable before tumors shed sufficient DNA into the bloodstream. Circulating tumor DNA (ctDNA)-based tests, while valuable in detecting advanced disease, face a fundamental biological constraint: in early-stage cancers, where tumor burden is low, DNA shedding is often intermittent or absent. As a result, ctDNA signals may only become reliably detectable after disease has progressed beyond the window of greatest clinical impact.

“The U.K. trial confirms that MCED blood testing can meaningfully shift the stage of cancer diagnosis. However, it also underscores that detecting the earliest cancers remains a fundamental biological challenge for ctDNA-based tests, as cancer biology does not begin with DNA fragment release in the bloodstream,” said Michael Lebowitz, Ph.D., Chief Scientific Officer of 20/20 BioLabs. “A scalable future for population screening will likely combine technologies, with sensitive protein biomarkers identifying risk earlier and genomic assays providing confirmatory precision.”

Studies published by 20/20 Biolabs and several independent research groups in the U.S. and Asia over the past 10 months add to the growing body of evidence that our company’s patented multi-cancer testing approach may help overcome many of the limitations of ctDNA for earlier stage detection:

• In May 2025 20/20 Biolabs presented data on the sensitivity of its OneTest for Cancer (Premium version) at the annual meeting of the U.S. National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), demonstrating detection rates for early-stage cancers as high as 50% for some tumor types — including pancreatic and ovarian cancers — from a pre-diagnostic (asymptomatic) population using a blinded cohort supplied by the NCI. (EDRN Poster May 2025)
• Additional support for using protein tumor markers comes from a large, multicenter validation study published in Nature’s Precision Oncology in October 2025, which evaluated an AI enhanced blood test integrating seven well established protein tumor markers (6 of which are part of OneTest) across more than 15,000 participants from seven centers in three countries (USA, China, and Brazil). The study demonstrated consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease and progressively higher detection rates as cancers advanced.
• In a blinded validation study published in November 2025, investigators at MD Anderson Cancer Center reported that a protein based multicancer test—with most of the same biomarkers measured in OneTest (Standard version)—identified nearly 90% of early stage lung cancers and flagged multiple other cancers a median of 12–21 months prior to diagnosis, supporting the sensitivity of protein tumor markers during early oncogenesis.
  
  

These recent reports build upon hundreds of studies over several decades showing the sensitivity of PTMs for early-stage detection of many different tumor types, especially following repeat (serial) testing. This evolving evidence reinforces the scientific and commercial rationale for large scale screening first with its protein biomarker-based OneTest for Cancer test prior to considering the more costly ctDNA tests or advanced imaging platforms.

“Given the higher sensitivity of protein-based tests for Stage I and II cancers, a tiered approach in which protein-based tests like OneTest serve as the initial screening step makes sense,” suggests Dr. Lebowitz. “Individuals identified by protein-based tests to be at mild risk can then be directed into ctDNA-based testing within a 3–6-month window, when ctDNA signals are more likely to be present. We believe those deemed at higher risk by protein–based tests are likely better served by moving directly to imaging studies. This tiered, or multi-step, approach is likely to yield the best outcomes and the lowest costs.”

Results from the ctDNA MCED trails in the U.K. come shortly after Congress passed legislation in February 2026 to create a pathway for Medicare coverage of MCEDs beginning in 2028.

“The reimbursement opportunity created by the new legislation is an important step forward for cancer screening access,” said Jonathan Cohen, CEO of 20/20 BioLabs. “As coverage decisions are made, we believe the science supports a broader view of MCED — one that includes protein-based technologies that have demonstrated meaningful early-stage detection. We are committed to continuing to build the evidence base and to working with policymakers, regulators, and payers to ensure that the most meaningful and cost-effective screening tools are readily available to Americans.”

About 20/20 BioLabs

20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for Longevity, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest’s affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD.

20/20 BioLabs’ pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab. The Company’s legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. For more information visit 2020biolabs.com.

Forward-Looking Statements

Certain statements in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, and financial needs. Forward-looking statements can be identified by words such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project,” “continue,” or the negative of these terms or other comparable expressions. Actual results may differ materially from those expressed or implied by such forward-looking statements. A number of factors could cause actual results to differ materially from those contained in these forward-looking statements, including, but not limited to, the risks described in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), available on the SEC’s website at www.sec.gov, including the Company’s Registration Statement on Form S-1, as amended (File No. 333-292125), as well as in our other reports filed or furnished from time to time with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events, except as required by applicable law. Although the Company believes the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee future results, and investors are cautioned that actual outcomes may differ materially from those anticipated.

Investor Relations 
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us

FAQ

What did 20/20 BioLabs (AIDX) report about OneTest sensitivity in May 2025?

OneTest (Premium) demonstrated detection rates up to 50% for some early-stage cancers in May 2025. According to the company, this result came from a blinded NCI-supplied cohort and highlights protein marker sensitivity in asymptomatic populations.

How did the October 2025 multicenter study support 20/20 BioLabs' PTM approach (AIDX)?

The Oct 2025 study across >15,000 participants showed measurable sensitivity in Stage I disease. According to the company, an AI-enhanced seven-protein panel produced consistent signals across diverse populations in USA, China, and Brazil.

What did the November 2025 MD Anderson validation say about protein tests and early detection (AIDX)?

MD Anderson reported a protein-based test identified nearly 90% of early-stage lung cancers and flagged cancers 12–21 months pre-diagnosis. According to the company, this supports PTM sensitivity during early oncogenesis and serial testing value.

What tiered screening strategy does 20/20 BioLabs (AIDX) propose and why?

20/20 BioLabs proposes starting with a protein-based OneTest, then using ctDNA or imaging for positives within 3–6 months. According to the company, proteins detect earlier risk while genomic assays provide confirmatory precision and cost-efficiency.

Does recent legislation affect Medicare coverage for MCEDs relevant to AIDX?

Congress passed legislation in Feb 2026 creating a pathway for Medicare MCED coverage beginning in 2028. According to the company, this reimbursement opportunity could expand access but will require continued evidence and payer engagement.

What limitations of ctDNA-based MCEDs did 20/20 BioLabs (AIDX) highlight in March 2026?

The company highlighted that ctDNA often is intermittent or absent in early-stage cancers, limiting early detection. According to the company, this biological constraint supports a complementary role for sensitive protein biomarkers.